# A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs

> **NCT04538313** · PHASE1,PHASE2 · UNKNOWN · sponsor: **CAR-T (Shanghai) Cell Biotechnology Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Hepatic Carcinoma

## Interventions

- **DRUG:** Tumor infiltrating lymphocyte

## Key facts

- **NCT ID:** NCT04538313
- **Lead sponsor:** CAR-T (Shanghai) Cell Biotechnology Co., Ltd.
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-26
- **Primary completion:** 2022-10-31
- **Final completion:** 2022-10-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2020-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04538313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04538313, "A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04538313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*